Heart failure & cardiomyopathiesDiagnostic or prognostic study
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model
- Prognostic model development and external validation study
- cause- and sex-specific Cox models
- age as timescale
- adjusted for competing risks
- external validation in 2 trials and 3 registries
Authors' conclusion
The LIFE-Preserved model enables prediction of short-term and lifetime risk of HF hospitalization or CV death in patients with HFpEF.
Study context
- Population
- Patients aged 40–90 years with HFpEF (LVEF ≥ 50%), Swedish heart failure (HF) Registry (derivation)derivation cohort
- Participants
- 20,332 patients
- Comparison
- Trials vs Registries
- Outcome
- HF hospitalization or CV death (model discrimination and calibration)
Performance
As reported in the abstract
Pooled C-statistic, external validation (HF hospitalization or CV death)
Trials
.714
pooled C-statistic · 95% CI .652-.775
Registries
.658
pooled C-statistic · 95% CI .599-.717
Further findings
HF hospitalization or cardiovascular (CV) death, derivation cohort · median follow-up 1.8 years (IQR .6-4.2, maximum 19 years)
- First HF hospitalizations or CV deaths, Swedish HF Registry
- 9341 (46%)
- First HF hospitalizations or CV deaths, external validation
- 9930 (35%)
Model performance by sex
- Performance similar in men and women
Original publication
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model. Eur Heart J. Published 11 March 2026. doi:10.1093/eurheartj/ehag182
Summarised from the published abstract; every number is checked against it